| [ Summary ] |
Adjuvant chemotherapy with gemcitabine is the worldwide standard of care for patients with resected pancreatic cancer, whereas the role of radiation therapy remains controversial. Although adjuvant therapy improved surgical results, the prognosis after curative resection remains poor. Recently, criteria for borderline resectable pancreatic cancer has been proposed, and a neoadjuvant strategy for potentially resectableçoræborderline resectableçpancreatic cancer is under investigation. However, no large randomised controlled trials have been reported to date. Moreover, an international consensus on the definition of borderline resectable pancreatic cancer has not yet been established. The usefulness of neoadjuvant therapy should be elucidated in future prospective clinical trials under the proper definition of resectability. |